CBB, It could be the recent formulary changes coupled with the recent Vascepa educational conferences/CE’s, and AMRN business strategies starting to pay off. Particularly formulary changes. It looks like we took shares from the generics and added some new scripts. For the reasons I stated, I expect the trend to continue gradually going forward. IMO.
Market Data 
Markets 
AI
